Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

AMS secures shareholder support for planned sale to H.B. Fuller

14 August 2026 · By · Wire by Fusion42

Published

14 August 2026

Topic

operational-macro

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at medtechdive.com →

◆ Verified

Fusion42 · 14 August 2026 · Fusion42 review

AMS has gained shareholder approval for its planned sale to H.B. Fuller, which will bring the tissue-healing company and H.B. Fuller into the markets for formulated biosurgicals and mechanical closures.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

This acquisition reshapes H.B. Fuller’s footprint in tissue healing and mechanical closures. You in medtech must consider how this consolidation opens both new market opportunities and competitive pressure in biosurgicals.

◆ Coverage

1 source · 14 Aug 2026

◆ Related on Wire

◆ Topics

Medtechmergers-acquisitionsmedtechbiosurgicalsshareholder-approvalcorporate-sale